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Methods: An analytic review of literature drawn from several fields of health care.
Results: The continuum construct is now part of public health evaluation systems for
HIV, and is increasingly used in public health and the medical literature. Issues with
the comparability and optimal design of care continuum models have been raised, and
their methodologic and theoretic underpinnings and scope of focus have been underaddressed. Review of relevant publications suggests that a key limitation of current models is their lack of measures reflecting incidence and mortality. Issues relating to continua
data being longitudinal or cross-sectional, definition of numerators and denominators for
each step, data sources, measures of timeliness of step completion, theoretic models
to facilitate inferences of causes of care continuum gaps, how measures of prevention
efforts, reinfection/relapses, and interactions of continua for co-occurring comorbidities
should be reflected, and how analyses of differences in retention over time, across geographic regions, and in response to interventions should be conducted are critical to the
development of sound care and prevention continuum models.
Conclusion: Lessons learned from the application of continuum models to HIV and
other conditions suggest that the application of well-formulated constructs of care and
prevention continua, that depict, in well defined, standardized steps, incidence and mortality, along with degrees of and time to screening, engagement in care and prevention,
treatment and treatment outcomes, including relapse or reinfection, may be vital tools in
evaluating intervention and program outcomes, and in improving population health and
population health metrics for a wide range conditions.
Keywords: care continuum, cascade of care, HIV, hepatitis C, treatment and prevention
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BACKGROUND

These methods have been used extensively in social and political
science (19, 20). They rely on comparisons between and inferences drawn from a modest number of cases (in this analysis;
“cases” refers to publications or applications of continuum constructs) (20). We then sought to review the historic development,
construction, and application of continuum models, the delineation of specific steps, observations about the clinical and public
health domains represented and not represented in the models,
and definitions and data sources.

The construct of “care continua” has become an important tool
in the evaluation and improvement of the overall care for certain
conditions (1–5). Examinations of prevention and care continuum
constructs have provided valuable insights into the progress of
individuals and populations through sequential steps of care, and
into barriers to such progress. While the construct has been in use
for some time, it has received increased attention and formalized
acceptance as part of the US’ “HIV care continuum initiative”
(3) and has now been integrated as part of formal public health
evaluation systems for HIV. The construct is also now a central
component of the Joint United Nations Programme on HIV/AIDS
(UNAIDS), and World Health Organization approaches to HIV
global public health; the UNAIDS goal of 90% diagnosed, 90% on
antiretroviral therapy (ART), and 90% virologically suppressed
(“90–90–90”) implicitly adopts a care-continuum framework
(6). In fact, the HIV continuum model has been referred to as an
effective and important tool “for improving the health of people
living with HIV and for achieving the public health benefits of
ART” (7) and for “measuring the performance of HIV care and
treatment programs (8).”
The construct of care continua is also being increasingly used
in other clinical and public health settings, such as in evaluations
of care systems for other infections, such as hepatitis C virus
(HCV), sexually transmitted infections (STIs) (5, 9, 10), and
non-communicable diseases (e.g., diabetes) (11, 12). However,
issues with their comparability and optimal design have been
raised, and their methodologic and theoretic underpinnings
and their scope of focus have been under-addressed (1, 13, 14).
Further, despite their increased use, continuum constructs have
not been formally or consistently applied to a wide range of other
conditions that might benefit from their use. This includes some
conditions that may not themselves currently be viewed through
a continuum of prevention and care lens, but that are frequently
identified as barriers to progress through the steps of continua
of other conditions, such as evaluations identifying an adverse
impact of substance use, misuse, and substance use disorders
(SUDs) on the HIV or HCV care continua (5, 15, 16).
Our goal is to more fully theorize the continuum construct
and to help develop understandings, definitions, and applications
of care continua so as to improve their use as valuable tools for
scientific, programmatic and public health evaluations and interventions generally. To achieve this goal, we will examine some
examples of the valuable application of continuum models and
explore issues with and limitations of existing models and make
suggestion for their improved use.

RESULTS
Early Applications and Basic
Considerations

The concept of care continua derive from the Piot and PiotFransen models for tuberculosis (TB) and STIs, respectively,
where models focused on operational considerations that arose
and that reduced the overall effectiveness of clinical and public
health efforts already demonstrated by studies to be efficacious
in idealized settings (4, 21, 22). The Piot-Fransen model has been
used to understand systems of STI care and the potential impact
of various interventions by considering, for example, a population of women and the proportion (1) with an STD, (2) who are
symptomatic, (3) seek treatment, (4) go to a health unit, (5) are
treated correctly, (6) are adherent, (7) are treated effectively, and
(8) whose partners are treated (21).
Continuum models are usually graphically represented as a
bar graph where each bar represents the proportion of persons
completing each step (3, 9, 23–25). In such depictions, if the
numerator in the first step is then taken to be the denominator
of the subsequent step (9), each step is essentially represented
as a separate event and the impact of cumulative losses through
sequential steps is visually de-emphasized. If, instead, the denominator is kept constant throughout sequential steps, the overall
impact of cumulative losses is made visually more apparent (25).
Hayes et al. depicted the progressively decreasing proportions of
persons completing each step, using visual descriptions of quantitative data to assess not only the losses occurring at each step
but also to allow estimates of the impact of different strategies,
such as the addition of interventions including active case finding, syndromic treatment, or mass community-level treatment,
on continuum progress and the impact of such interventions on
population health (21).

Valuable Applications of Continua
Constructs

HIV likely represents the most established and successful
application of a continuum model. More recent applications
of continuum models for the prevention of maternal-to-child
transmission of HIV and for HIV care generally (26, 27) yielded
valuable insights and introduced methods for both measuring
the progress of individuals and populations (2, 3, 15, 23). The
Centers for Disease Control and Prevention (CDC) formally uses
two well-defined approaches to evaluate the HIV continuum
models with the specific intent of both gauging progress toward
specified public health goals and of directing HIV prevention

METHODS
Examined literature comes from several fields of social science,
health care and public health over several decades. In order to
explore the continuum construct through a variety of lenses,
we adopted an analytic and synthetic approach to draw lessons
from these diverse sources. This approach relied on traditional
literature review search methods and on the application of the
case study methodology and the comparative method (17, 18).
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resources most effectively (3). Both continuum models consist
of the same five steps but employ different denominators. The
steps specified in both of these CDC models are the proportions
diagnosed, linked to care, engaged or retained in care, prescribed
antiretroviral therapy, and virally suppressed (1, 3, 28). These
steps correspond to measurable outcomes with clinical and public
health relevance.
One model, “the prevalence-based HIV care continuum,”
examines each specified step as a proportion of the total
number living with HIV including those diagnosed and those
undiagnosed. The other model, “the diagnosis-based HIV care
continuum,” uses as a denominator the total number of those diagnosed with HIV excluding those who have not been diagnosed.
The prevalence-based model can be used to assess outcomes for
broad populations such as young women, but not subgroups of
these populations, e.g., low-income young women. In contrast,
the diagnosis-based model allows examination of more detailed
population subgroups referred to as stratified continuum models.
Similarly, continuum models are also proving valuable in
identifying gaps and focusing resources for HCV, TB, and other
services (5, 11, 29). Analyses of the TB continuum led to the observation that non-adherence to TB treatment was one key obstacle
to effective completion of TB treatment (30); directly observed
therapy for TB was developed in response to this observation
to address treatment adherence, to promote progress through
the TB continuum and reduce the development of acquired
resistance, and to reduce ongoing transmission (31, 32). Indeed,
continua conceptual models for HIV and HCV, and strategies to
promote engagement and retention, and deter the development
of acquired drug resistance, have been potently informed by
global experience with, and continuum-based analyses of, TB
public health systems and the strategies employed.
Despite the contributions already made through the use of
continuum models in HIV and other fields, there are a number
of key issues central to their optimal use as evaluation tools generally that require further consideration. These include issues of
theory; the delineation of specific steps standardization; reflecting incidence, time, and disease-specific morbidity and mortality;
and statistical analysis of the models that will be addressed in the
sections that follow.

(34, 35). This may facilitate the identification of multi-level factors impacting individual progress through the continuum, as
well as examine how progress through continuum steps reflects
and impacts population-level health (36).
There are frequently large time gaps between demonstrations
of efficacy and implementation in practice (37). Continua models
can help focus attention on issues critical to the effectiveness and
implementation of care and prevention interventions (31). For
example, there are highly efficacious drugs available to treat TB
(i.e., they work very well under optimized conditions). However,
despite this, there are many impediments to TB elimination
which are predominately “operational,” i.e., the real-world
effectiveness of these efficacious drugs is reduced by a range of
multi-level barriers (38, 39). Similarly, there are also now highly
efficacious drugs for HCV offering the potential for a cure; however, here, the real world effectiveness of these agents is undercut
by issues of cost and resultant processes that restrict access
(40, 41). Continuum models viewed through appropriate multilevel theory are useful in identifying and guiding efforts that
address barriers and disparities.

Defining the Steps in a Continuum Model

The steps of any specific continuum model should reflect the
specific clinical features of that condition and actual processes
of prevention and care and should be chosen to facilitate elucidation of potential barriers to progress through the continuum so
that discrete barriers can be addressed. Many continua models
begin with an initial step of awareness of risk or a condition and
whether individuals may seek attention or of active testing, case
finding, or screening of either high-risk or general populations to
identify those with the condition in question (5, 42). Commonly
these steps need to be followed by steps of further evaluation and
engagement and retention in care. The construct “seek, test, treat,
and retain” is one HIV continuum paradigm that emphasizes this
common sequence of steps (43). However, in these constructs, the
category “test” or “screen” may mean a range of things that may
need to be subdivided into components for optimal monitoring,
implementation, and improvement. For example, testing can
refer to HCV antibody testing with or without confirmatory viral
load testing. Clear characterization of each step can allow specific
decisions to be made about choice architecture questions, such as
whether testing is offered as “opt in” or as “opt out” (the use of specific defaults can significantly improve specific care continuum
steps) or whether confirmatory testing, where needed, should be
done as an automatic reflex (44–46).

Use of Theoretic Frameworks

An identification of gaps does not in and of itself provide an
understanding of the reasons for such gaps. An understanding
of reasons for gaps in or barriers to the progress of individuals or
populations through the steps of care requires the application of
an appropriate theoretic framework. Where continuum analyses
are guided by an appropriate theoretic model, factors affecting
progress through sequential steps can be more fully examined; for
example, some studies demonstrate the importance of structuraland individual-level factors as determinants of progress through
continua (16, 33). This is important because the framing as “care”
continua focuses attention primarily on clinical or biologic endpoints and may, therefore, de-emphasize key explanatory factors
that fall outside of traditional medical care systems. Eco-social
theory and the population health approaches of Krieger and
Rose, respectively, may be valuable underlying theoretic models
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Reflecting Incidence in Continua Models

One key limitation of beginning a continuum model with the
steps of seeking or testing is that the model then may fail to reflect
a key public health indicator of disease: incidence. Continuum
models often begin with the proportion of a general or knownto-be-positive population who are screened (3, 28). Thus, screening does not distinguish between prevalent or incident cases.
Further, models that start with the number of positive cases,
or those diagnosed as the denominator (as in both CDC HIV
models), rest entirely on prevalence. Implicit in standard HIV
continuum models is the notion that increases in the proportion
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of individuals tested and treated will translate to reductions in
incidence; however, the failure to distinguish between prevalent
and incident cases and the failure to reflect measures of incidence
in the model inappropriately de-emphasizes the importance of
incidence as a public health indicator, may obscure detection
and consequences of changes in incidence, and may contribute
to suboptimal allocation of resources. Distinguishing between
prevalent and incident cases and to reflect measures of incidence
in continuum models would improve their value as public health
tools.

Further, diagnostic evaluations are often individualized by
providers influenced by hidden cognitive processes related to
the providers’ estimation of a patient’s resources, often within
constraints imposed by patients, organizations, and insurers
(51). These organizational constraints (e.g., prior authorizations)
may themselves pose barriers to medical evaluation completion
and care continuum progress (40, 52, 53). Similarly, providers, in
response to guidelines or unconscious biases, differentially apply
“eligibility criteria” in ways that constituting a “stutter-step” in
health-care provision, and introducing health disparities (25, 51).
Further, these evolving factors may lead to variability that poses
issues for standardized analyses.

Reflecting Prevention in Continua
Models

Methodologic Issues in Continuum Models

Continua constructs may be valuably applied to prevention
as well as to care where initial testing or screening are crucial
both in identifying those affected by the specified condition and
those who may be at risk for but not yet have the condition (8).
Most continuum models exclude those testing negative from
subsequent consideration. Those who test negative for HIV,
or other specified conditions, may, nonetheless, be at risk and
consequently require linkage to prevention services, require
retention in such services, and may require efforts at adherence
support for risk reduction interventions. In fact, the reliance on a
step of testing or screening in many continua models, which may
identify both those already affected and those at risk, highlights
the importance of understanding continua models as more than a
linear progression of steps of those affected, but of seeing care and
prevention as linked and inter-related. As McNairy and El-Sadr
highlight, the step of testing and screening serve as a critical point
of intersection between the HIV prevention and care continua
models (8); however, developing separate prevention and care
continuum models may miss or obscure the bi-directional relationships between prevention and care that might be revealed by
an integrated model. Consequently, one key consideration for
delineating steps in a continuum model is that of appropriately
representing factors that relate to primary prevention.

Lourenco et al. have noted that HIV continuum models used
different countries vary both in enumerated steps and definitions of steps and argue for the need for standardization of the
HIV continuum construct to allow continuum comparisons
(14). As discussed in Section “Early Applications and Basic
Considerations,” the clearly delineated and well-standardized two
CDC HIV continuum models have proven to be valuable constructs. Yet, while these two main models may provide different
and complementary information, since the numbers of persons
with HIV who have not been diagnosed can only be estimated not
directly measured, they may give different estimates for proportions at each of the defined steps (54). Further, both models are
based on cross-sectional surveillance data and evaluate outcomes
for the aggregate population studied in a single year and do not
necessarily reflect individual-level continuum progress. Another
model being applied in some settings is to examine the continuum
among those with newly diagnosed HIV (another potentially
valuable stratification); this model facilitates incorporating considerations of time elapsed between steps, such as the proportion
achieving viral suppression in the 12 months following diagnosis.
A recent systematic review of publications examining HIV
continuum models focusing on data sources, methodology,
and study comparability with respect to these parameters (13).
Analyses were restricted to published data of HIV care continua
in well-defined populations, and further restricted to studies
providing viral suppression data and explicit methods. Despite
these rigorous inclusion criteria, the authors identified significant
variability both in the number of steps delineated, and in the data
source used for steps reported on in the included studies. There
was also moderate variability in the definitions used to delineate
both numerators and denominators at each of the steps (e.g.,
different approaches were taken to handling persons who may
have died, moved away, or been incorrectly notified). A variety
of time frames or attendance requirements were used in defining linkage to care, and there was heterogeneity in definitions of
what contributed to the numerator of those “on ART,” as well as in
what cut-off constituted virologic suppression. The authors point
out the potential value of comparisons of continuum analyses
stratified by geographic regions and time, and among groups, but
stress the critical importance for consistency in methodology and
definitions to make such comparisons valid.
Another recent paper examined an 8-step HIV continuum
model and conducted sensitivity analyses based on variations in

Connections between Diagnosis and
Treatment in Continua Models

The issue of the connection between screening and acting on the
results of screening was highlighted by John Sbarbaro in an editorial entitled “To seek, find, and yet fail” written in response to a
novel TB skin testing program, which identified a high prevalence
of latently infected persons and yet included no efforts to link
such persons to evaluations to exclude active TB or initiate treatment of latent TB infection (47). This issue of ensuring effective
connections between steps of identification and diagnosis, and
subsequent linkage to and initiation of care, emerge as common
and critical to care continua for multiple conditions. Approaches
to reducing gaps after screening include interventions, such as
patient navigators, or of locating testing and care in community
settings or in settings where specific risk groups convene (48).
Significant experience in HIV, HCV, and TB care suggests that
processes of passive referral to treatment after screening yield
inferior linkage outcomes compared with systems of active linkage (10, 49, 50).
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continua definitions (55). They found that requiring or not requiring CD4 cell count and viral load testing as part of definitions of
being linked to care changed proportions of those doing so up to
18%. Definitions of being on ART (which required at least two
medication dispensations at least 3 months apart) yielded rates
20% lower than definitions requiring any ART in that calendar
year. Overall, they found that the step most sensitive to variations
in definition was that of the last step, viral suppression. A rigorous
definition requiring two suppressed viral load determinations at
least 3 months apart classified 49% as virologically suppressed,
a proportion 15–25% less than definitions requiring a single
undetectable viral load.
Overall, these issues highlight the potential impact of variations in definitions on measured outcomes and the need for definitional clarity and sensitivity analyses.

Use of continuum models that reflect longitudinal rather
than cross-sectional data may be particularly important for
understanding chronic conditions. For example, if a gonorrhea
or syphilis case is diagnosed in any given year (where treatment
can be a single dose or a brief course), treatment and cure should
be obtained within that same year; a cross-section analysis
would reflect this. Alternatively, for conditions requiring longer
treatment (e.g., HIV), cross-sectional analyses may overestimate
continuum progress.

Endpoints for Continua Models: Relapse,
Reinfection, and Mortality

For both HIV and HCV, a key continuum “endpoint” of viral
suppression will remain relevant and vital. The rationale for the
importance of this endpoint is the excellent data that viral load
suppression translates both into individual-level quality health
outcomes and population-level conditions that result in lower
likelihoods of transmission with subsequent reductions in incidence which might then lead to epidemic control, elimination,
and theoretically eradication (59, 60). Post-viral load suppression
for HIV or HCV, it will be important to assess rates of relapse
or reinfection. Similarly, for TB continua models, the common
endpoint is a mixture of smear and culture conversion and
completion of a duration of therapy shown in efficacy studies to
translate to low rates of treatment failure, relapse, and secondary
transmission. Yet while such valuable biological measures are
generally depicted as continua endpoints, a critical appraisal of
care continua suggests the need to reflect reinfection and relapse.
Further, virologic suppression or any other biologic or behavioral outcome measures are at best surrogates of the fundamentally more critical endpoint of mortality. The nineteenth century
physician and epidemiologist William Farr noted that “the death
rate is a fact. Everything else is an inference” (61). Issues such
as whether antiretroviral treatment for HIV infection initiated
promptly at diagnosis regardless of CD4 count and taken with
adherence for decades translates to overall improved mortality,
or whether competing increases in cardiovascular or other forms
of mortality, associated or not associated with long-term ART
use, may emerge, are open questions and would be missed by
continuum analyses that stop at an outcome of viral suppression.
Therefore, continua models would be more meaningful if the final
step represented overall mortality or mortality attributable to the
process being evaluated.

Representing Time in Continuum
Constructs

In current continuum models, the depiction of sequential steps
along an axis does not represent the time required for transitions
from one step to the next. For example, the HIV continuum does
not convey the fact that many people are diagnosed late in the
course of their infection (52). It also does not convey the timeliness of linkages to care or of achieving viral suppression. Both of
these are central to the success of treatment as prevention yet they
are absent from typical HIV continuum constructs. Developing
models that measure the time between screening, treatment, and
treatment outcomes would be important.
Another key aspect of prevention and care relates both to the
defined population and to the recognition that populations are
not stable overtime (56). For example, continua models are often
applied to specific geographic regions and individuals may move
into or out of regions, with consequences both in interruptions in
their own individual progress through continua and with implications for how to accurately count such individuals. These considerations may lead to inaccurate assessments of the proportions of
persons at any given continuum step and require standardization
to allow appropriate comparisons across geography and over time
(13). With respect to HIV continua, this issue has been referred
to as “churn” and has been recognized as leading to inaccurate
estimates of the number of HIV-infected persons and hence, their
representation in continua models (54, 57).
Another issue is whether continuum analyses examine
cross-sectional or longitudinal data, a critical distinction where
achieving outcomes takes variable amounts of time and where
outcomes must be sustained overtime. Colasanti et al. examined
continuous retention in care and continuous viral load suppression over 36 rather than 12- or 24-month periods (1) using
generalized estimating equations with a logit link and Poisson
regression log-link tests to evaluation retention in care and the
prevalence ratio of viral suppression over time, respectively (58).
Single cross-sectional analyses were found to potentially overestimate retention and virologic outcomes, and that longitudinal
continuum constructs may better describe long-term outcomes
and reveal disparities potentially obscured by cross-sectional
annual examinations.

Frontiers in Public Health | www.frontiersin.org

Interacting Continua for Multiple
Conditions

Another issue to be addressed relates to the reality that individuals
may have more than one health condition, so that an individual
may in fact be moving through multiple continua which may be
interrelated to varying degrees. For example, for individuals with
HIV/HCV, coinfection will be considered as part of both HIV
and HCV continuum, respectively, and at an individual-level will
need to move through the steps of both as part of optimal health
care.
Movement through continuum for two or more conditions
are likely to be impacted by the specifics of the service delivery
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systems, which would include whether care occurs through an
integrated system that addresses all of the conditions or whether
care is delivered through separate systems. Broadly speaking, this
relates to the issues of vertical versus horizontal models of care
and public health funding streams (62, 63). Specifically, it relates
to a wide variety of models of co-located services such as whether
HCV care is delivered within an HIV and SUD care setting or if
individuals are referred elsewhere (64). In fact, use of continuum
models for single conditions in some sense reproduces and
reinforces systems of vertical care which have the potential to
both create barriers themselves and to reframe and de-emphasize
aspects of care for persons with commonly occurring comorbidities. To the extent that certain conditions assessed through the use
of continua are highly overlapping, the use of a disease-specific
continuum to inform resource allocation may be misleading or
may miss opportunities for enhanced efficiencies (65).
Movement through one specific continuum may also be
directly tied to movement through another continuum. Providers
may make the decision to prioritize achieving HIV viral suppression prior to the initiation or consideration of HCV treatment; in
fact, some treatment guidelines and insurance policies suggest or
“mandate” this (40, 53). In that sense, achieving certain steps of
HIV prevention and care might appropriately be construed as part
of a HCV continuum model. Similarly, care systems for HCV may
require screening for and treatment of SUDs (52). As an example
of interacting care continua, for persons with HIV-related TB,
the fact that TB treatment should precede ART initiation, and
that in analyses the need for TB treatment is associated with late
ART initiation, demonstrates that progress through these two
care continua are linked (66). This highlights the need for models
that clearly delineate the relationships between progress through
co-occurring care continua.
Understanding that conditions identified as potential barriers
to progress through a continuum for one condition may in fact
be disorders requiring intervention, may allow improved understanding of the interaction of care systems and of how conditions
may act as barriers, and may allow the development of more
refined variables.

for later stages (e.g., there is no HCV treatment initiation without
HCV medical evaluation completion). Several formal quantitative analytic methods may be particularly valuable. In formal
analyses, achieving sequential continuum steps may be viewed
as a count variable. One approach could be to use the continuous
ratio model (CRM) which is well suited to sequential outcomes
of this type (68). With a logit link, exponentiated regression coefficients could indicate how the odds of progressing to a sequential
continuums stage are affected by an intervention, in terms of an
odds ratio. The CRM is equivalent to discrete-time survival analysis (69–71) where a continuum step would correspond to time
periods in survival analysis. Further, for longitudinal continuum
analyses, generalized estimating equations with a logit link or
Poisson regression log-link tests, as employed by Colasanti et al.
may be valuable (1, 58).
In analyzing progress through sequential steps is the consideration of whether each step requires comparable effort or
results in comparable public health impact. Steps then may need
to be weighed based on the varying on these considerations. One
consideration is also whether the steps of a continuum should
(or do) represent critical individual-level or population-level
milestones, or whether they primarily reflect measurable milestones, and these may not be the same thing. It might be that
shifting a continuum curve in which an improvement of some
proportion at one step may not translate to relevant gains in
population health, while an improvement of the same proportion at another step might do so (35). This may especially be
so if the continuum is primarily focused on care and not on
prevention or other public health metrics, such as incidence,
timeliness of achieving specified outcomes, or deaths among
those out of care. Hence, at an individual-level, weights might
be assigned to steps on the basis of estimates of their relative
degrees of difficulty, and at a population-level weights might be
assigned on the basis of estimates of their relative importance to
population health gains.
This leads to the issue of whether continuum steps are of necessity sequential, or should always be viewed so representationally
or analytically. Qualitatively, it has been abundantly noted that
individuals may complete any given step of a continuum model
and for a range of reasons, not proceed to the next clinically
logical or desired step, but then at some subsequent point in time
become re-engaged at the same or even re-enter at an earlier step
in the continuum model (72). Such stalled or backward movement may be the result of various barriers introduced by both
providers and patients (e.g., losing health insurance) as part of a
“stutter-step” (51). In most continuum models, the presumption
is that those represented in the numerator of one step of necessity
were in the numerator of the prior step. Yet, Magnal et al. identified individuals in an HIV continuum analysis who did in fact
meet definitions for having been prescribed ART or even being
virologically suppressed but did not meet definitions for having
been retained in care (24). In their comparison, categorization
of continuum stages as dependent subsets of prior stages led
to underestimates of those prescribed ART or achieving viral
suppression.
An underutilized potential of continuum analyses is their
application to evaluating the impact of interventions to improve

Data Sources for and Analyses of
Continua Constructs

Central to the development of any continuum model is the issue
of identifying appropriate data sources for each of the identified
steps. For HIV and TB, such data sources are reasonably well
developed (67). Current models have relied on combinations of
information derived from laboratory-based reporting and clinical
care data, data which are often collected for specific health-care
systems or regions, which directly inform continua constructs
that describe these jurisdictions. Their use to populate models
that combine jurisdictions may lead to inaccurate estimates unless
careful methods are applied to identify duplicate cases (54). Large
national databases and electronic medical record systems may be
useful data sources for continua and further may facilitate the
examination of interconnections between related models.
In formal analyses, continuum progress could be viewed a
sequential ordinal variable where earlier stages are prerequisites

Frontiers in Public Health | www.frontiersin.org

6

January 2017 | Volume 4 | Article 296

Perlman et al.

Developing Improved Care and Prevention Continua

the steps of care. Hayes et al. used graphical representations of
STI continuum outcomes to estimate the potential impact of different public health strategies on STI outcomes (21). Quantitative
analyses might consider interventions as either time-invarying
or time-varying exposures. In quantitative analysis, interventions
attempting to improve progress through sequential continuum
steps might in theory be viewed as a time-invarying exposure
reflecting being on treatment or not. However, because intervention components may vary in content or emphasis through
each step, interventions addressing multiple steps may be better
viewed as a time-varying exposure. Similarly, covariates may have
differential impact on different steps and, therefore, may represent time-varying confounders, while also potentially being on
the causal pathway. This suggests that marginal structural models
may be valuable analytic strategies for evaluating the impact of
interventions (70, 73).

relationships between a given continuum and continua for key
comorbidities (57, 74).

Limitations

In reviewing the literature from several fields using traditional
literature review search methods, some important contributions
may have been missed and selection bias could have introduced.
However, the review of literature from multiple fields serves
as a form of triangulation which may ameliorate this risk
(75, 76). Some topics meriting discussion may not have been
optimally covered; decisions were made in an effort to balance
comprehensiveness and focus. Further, the goals of and specific
considerations relevant for models intended specifically for questions unique to either specific health-care systems or to unique
populations within the substance use field may not have all been
fully incorporated.

CONCLUSION

DISCUSSION

Well-constructed and standardized continua models are proving to be invaluable for program development, evaluation and
policy, for public and private health systems in standardizing and
evaluating outcomes, informing study design, modeling, resource
allocation, and for facilitating standardized comparisons of an
expanding range of health outcomes across programs, states, and
countries. Review of lessons learned from the valuable application
of continuum constructs suggests that steps of the awareness, of
screening, of linkage to evidence-based treatment and retention
in such treatment, and of monitoring timely movement between
steps, incidence, relapse/reinfection, and mortality. How best to
reflect some of these factors will require more consideration and
development. Identifying optimal data sources for continuum
steps and standardizing definitions for these steps and of relevant numerators and denominators will be needed. Similarly,
optimizing methods for quantitative analysis of progress through
continua and of the impact of interventions on such progress is
also needed.
In conclusion, the application of well-formulated constructs of
care and prevention continua, that depict, in well defined, standardized steps, incidence and mortality, along with degrees of and
time to screening, engagement in care and prevention, treatment,
and treatment outcomes including relapse or reinfection, may be
vital tools in evaluating intervention and program outcomes and
in improving population health and population health metrics for
a wide range conditions.

Implications for Improved Use of
Continuum Models

Review of the literature suggests several key implications for the
improved use of continua models as clinical and public health
tools. Models would optimally reflect incidence and distinguish
incident and prevalent cases. They should reflect disease-specific
and all-cause morbidity and mortality. Optimal models would
reflect relapses and reinfections, as well as measures of primary
and secondary prevention. Models should also reflect the timeliness between steps and have explicit and appropriate definitions,
data sources, and means for handling those who move or die.
Models should be understood to require the use of theoretic
frameworks that consider structural as well as individual causes
of identified gaps.
Numerous issues in the delivery of care and prevention for
many conditions resemble those identified in the HIV, HCV,
and TB continua, including issues of underdiagnoses, gaps in
linkages between screening and initial diagnosis and engagement in treatment, issues in treatment retention, adherence,
and relapse, and the interdigitation of continua for relevant
comorbidities. Systems of care and prevention for many conditions can appropriately and usefully be viewed as consisting of
a care and prevention continuum including steps of incidence,
screening/identification, medical/psychosocial evaluation for
treatment, engagement in evidence-based treatment, retention
in treatment through to well-defined measures of treatment
success, as well as degrees of engagement in evidence-based
interventions to prevent relapse, and measures of overall and
substance-related-specific mortality. It would be critical to
define the denominator most relevant to each specified step.
As with HIV and other continua, the use of various population
denominators will be important in addressing different questions. It would be essential to identify appropriate data sources
for each step, relevant and valid measures of treatment success,
standardized definitions of numerators and denominators, and
standard methods to account for those who move or die, and
handling missing data. It would also be appropriate to reflect
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